Table 2.

All adverse events grade ≥3 occurring in ≥2 patients

	Q3W dosing					Q1W dosing		All patients (N = 39)
	0.3 mg/kg (n = 3)	0.6 mg/kg (n = 3)	1.2 mg/kg (n = 3)	1.8 mg/kg (n = 7)	2.4 mg/kg (n = 17)	0.8 mg/kg (n = 3)	1.1 mg/kg (n = 3)
Any AE	1 (33.3%)	2 (66.7%)	0	1 (14.3%)	8 (47.1%)	1 (33.3%)	2 (66.7%)	15 (38.5%)
Infections and infestations	1 (33.3%)	1 (33.3%)	0	0	0	1 (33.3%)	1 (33.3%)	4 (10.3%)
Neutropenia	1 (33.3%)	0	0	0	3 (17.6%)	0	0	4 (10.3%)
Nervous system disorders	0	1 (33.3%)	0	0	2 (11.8%)	0	0	3 (7.7%)
Alanine amino-transferase increased	0	0	0	1 (14.3%)	1 (5.9%)	0	0	2 (5.1%)
Anemia	0	0	0	0	1 (5.9%)	0	1 (33.3%)	2 (5.1%)
Aspartate amino-transferase increased	0	0	0	1 (14.3%)	1 (5.9%)	0	0	2 (5.1%)
Hyperglycemia	0	0	0	1 (14.3%)	1 (5.9%)	0	0	2 (5.1%)
Hyponatremia	0	0	0	0	2 (11.8%)	0	0	2 (5.1%)
Musculo-skeletal and connective tissue disorder	0	1 (33.3%)	0	0	1 (5.9%)	0	0	2 (5.1%)
Renal failure acute	0	0	0	0	2 (11.8%)	0	0	2 (5.1%)
Thrombo-cytopenia	0	0	0	0	2 (11.8%)	0	0	2 (5.1%)